Cited by 94Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion

Oeckl, Patrick, Anderl-Straub, Sarah, Von Arnim, Christine A F, Baldeiras, Inês, Diehl-Schmid, Janine, Grimmer, Timo, Halbgebauer, Steffen, Kort, Anna M +9 more·2022·Journal of Neurology, Neurosurgery & Psychiatry

Abstract

Objective: Reactive astrogliosis is a hallmark of Alzheimer’s disease (AD) and frontotemporal dementia (FTD) but differences between the diseases and time course are unclear. Here, we used serum levels of the astroglial marker glial fibrillary acidic protein (GFAP) to investigate differences in patients with AD dementia, mild cognitive impairment (MCI)-AD and behavioural variant FTD (bvFTD). Methods: This multicentre study included serum samples from patients diagnosed with AD dementia (n=230), MCI-AD (n=111), bvFTD (n=140) and controls (n=129). A subgroup of patients with MCI-AD (n=32) was longitudinally followed-up for 3.9±2.6 years after sample collection. Serum levels of GFAP, neurofilament light chain (NfL) and pTau181 were measured by Simoa (Quanterix) and Ella (ProteinSimple). Results: In total, samples from 610 individuals from four clinical centres were investigated in this study. Serum GFAP levels in AD dementia were increased (median 375 pg/mL, IQR 276–505 pg/mL) compared with controls (167 pg/mL, IQR 108–234 pg/mL) and bvFTD (190 pg/mL, IQR 134–298 pg/mL, p<0.001). GFAP was already increased in the early disease phase (MCI-AD, 300 pg/mL, IQR 232–433 pg/mL, p<0.001) and was higher in patients with MCI-AD who developed dementia during follow-up (360 pg/mL, IQR 253–414 pg/mL vs 215 pg/mL, IQR 111–266 pg/mL, p<0.01, area under the curve (AUC)=0.77). Diagnostic performance of serum GFAP for AD (AUC=0.84, sensitivity 98%, specificity 60%, likelihood ratio 2.5) was comparable to serum pTau181 (AUC=0.89, sensitivity 80%, specificity 87%, likelihood ratio 6.0) but superior to serum NfL (AUC=0.71, sensitivity 92%, specificity 49%, likelihood ratio 1.8). Conclusions: Our data indicate a different type of reactive astrogliosis in AD and bvFTD and support serum GFAP as biomarker for differential diagnosis and prediction of MCI-to-dementia conversion.

Integrity signals

Registry

Crossref · 10.1136/jnnp-2021-328547

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., Ortner, M., Santana, I., Steinacker, P., Verbeek, M. M., Volk, A. E., Ludolph, A. C., & Otto, M.
Affiliations
  • Universität Ulm (DE)
  • Unidade Local de Saúde de Coimbra (PT)
  • Technical University of Munich (DE)
  • Radboud University Nijmegen (NL)
  • University of Coimbra (PT)
  • University Medical Center Hamburg-Eppendorf (DE)
Corresponding author
Otto, Markus
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2022-04-27
Volume
93
Issue
6
Pages
659-667
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W4225095672
Cited by
94
References
32
Citations by year
2026: 10 · 2025: 33 · 2024: 30 · 2023: 18 · 2022: 3
FWCI
13.67
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • DZNE Pub (submittedVersion)
Funders
  • German Federal Ministry of Education and Research (FTLDc 01GI1007A)
  • Foundation of the state Baden-Württemberg (D.3830)
  • Boehringer Ingelheim Ulm University BioCenter (D.5009)
  • German Research Foundation/DFG (SFB1279)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
glial fibrillary acidic protein, serum biomarkers, Alzheimer's disease, frontotemporal dementia, behavioral variant frontotemporal dementia, mild cognitive impairment, reactive astrogliosis, neurofilament light chain, p-tau181, differential diagnosis, diagnostic accuracy, longitudinal follow-up, Simoa, ELISA

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review